0625/26SCR019-18/R12RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
5
Mabel Mardones, MD
SCRI at Rocky Mountain Cancer Centers I The US Oncology Network
Media Outlet Date Article / Coverage
eCancer 6/10/26 Giredestrant Plus Palbociclib Shows Limited Benefit in ER-
Positive, HER2-Negative Metastatic Breast Cancer
Oncology Learning
Network
6/18/26 Giredestrant Demonstrates Favorable Safety Profile but
Fails to Significantly Improve PFS in HR-Positive, HER2-
Negative Metastatic Breast Cancer
Meredith McKean, MD, MPH
SCRI
Media Outlet Date Article / Coverage
OncLive 6/16/26 Experts Weigh In on Some of the Most Impactful Data in
Melanoma From ASCO 2026
Targeted Oncology 6/2/26 Targeting the IL-2 Pathway to Overcome Immunotherapy
Resistance in Melanoma
Krish Patel, MD
SCRI
Media Outlet Date Article / Coverage
eCancer 5/30/26 ASCO 2026: Combining Targeted Immunotherapies
With Standard R-Chop Delays Progression of Aggressive
B-Cell Lymphomas
Endpoints 5/28/26 After Leaving Legend, Founding Scientist Frank Fan Is
Ready to Showcase His Next Project
Endpoints 6/1/26 ASCO in Brief: Lilly's Plenaries; Incyte's Frontline Data
in Lymphoma
Continued ➔
